OBJECTIVES: The objectives of this study were to determine the effect of aging, schizophrenia, and their interaction on cognitive function. DESIGN: Cross-sectional controlled study. SETTING: Community living. PARTICIPANTS: A total of 235 subjects with schizophrenia age 19-79 and 333 comparison subjects age 20-81. MEASUREMENTS: The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). RESULTS: Older age was associated with poorer performance on 9 of 10 MCCB tests in both subjects with schizophrenia and comparison subjects. Subjects with schizophrenia were impaired relative to comparison subjects on each of the 10 tests. However, there was no interaction between aging and schizophrenia on any test. Essentially the same results were observed when analyzing performance on the seven MCCB cognitive domains and MCCB global composite score. CONCLUSIONS: Consistent with other reports, schizophrenia appears to be a disorder marked by generalized cognitive dysfunction. However, the rate of cognitive decline appears to be similar to that observed in healthy comparison subjects. They do not experience acceleration in cognitive aging, which supports the hypothesis that schizophrenia is a syndrome of premature aging. Longitudinal studies including very old patients are needed to confirm and extend these findings.
OBJECTIVES: The objectives of this study were to determine the effect of aging, schizophrenia, and their interaction on cognitive function. DESIGN: Cross-sectional controlled study. SETTING: Community living. PARTICIPANTS: A total of 235 subjects with schizophrenia age 19-79 and 333 comparison subjects age 20-81. MEASUREMENTS: The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). RESULTS: Older age was associated with poorer performance on 9 of 10 MCCB tests in both subjects with schizophrenia and comparison subjects. Subjects with schizophrenia were impaired relative to comparison subjects on each of the 10 tests. However, there was no interaction between aging and schizophrenia on any test. Essentially the same results were observed when analyzing performance on the seven MCCB cognitive domains and MCCB global composite score. CONCLUSIONS: Consistent with other reports, schizophrenia appears to be a disorder marked by generalized cognitive dysfunction. However, the rate of cognitive decline appears to be similar to that observed in healthy comparison subjects. They do not experience acceleration in cognitive aging, which supports the hypothesis that schizophrenia is a syndrome of premature aging. Longitudinal studies including very old patients are needed to confirm and extend these findings.
Authors: Jovier D Evans; Robert K Heaton; Jane S Paulsen; Barton W Palmer; Thomas Patterson; Dilip V Jeste Journal: Biol Psychiatry Date: 2003-03-01 Impact factor: 13.382
Authors: Barton W Palmer; Mark W Bondi; Elizabeth W Twamley; Leon Thal; Shahrokh Golshan; Dilip V Jeste Journal: J Neuropsychiatry Clin Neurosci Date: 2003 Impact factor: 2.198
Authors: R S Wilson; L L Barnes; N T Aggarwal; P A Boyle; L E Hebert; C F Mendes de Leon; D A Evans Journal: Neurology Date: 2010-09-01 Impact factor: 9.910
Authors: J I Friedman; P D Harvey; T Coleman; P J Moriarty; C Bowie; M Parrella; L White; D Adler; K L Davis Journal: Am J Psychiatry Date: 2001-09 Impact factor: 18.112
Authors: Tarek K Rajji; Benoit H Mulsant; Shinichiro Nakajima; Fernando Caravaggio; Takefumi Suzuki; Hiroyuki Uchida; Philip Gerretsen; Wanna Mar; Bruce G Pollock; David C Mamo; Ariel Graff-Guerrero Journal: Am J Geriatr Psychiatry Date: 2016-08-02 Impact factor: 4.105
Authors: Luz H Ospina; Melanie Wall; Lars F Jarskog; Jacob S Ballon; Joseph McEvoy; Matthew N Bartels; Richard Buchsbaum; Richard P Sloan; T Scott Stroup; David Kimhy Journal: J Psychiatr Brain Sci Date: 2019-12-30
Authors: Saba Shahab; Benoit H Mulsant; Melissa L Levesque; Navona Calarco; Arash Nazeri; Anne L Wheeler; George Foussias; Tarek K Rajji; Aristotle N Voineskos Journal: Neuropsychopharmacology Date: 2018-12-20 Impact factor: 7.853
Authors: William S Stone; Raquelle I Mesholam-Gately; Anthony J Giuliano; Kristen A Woodberry; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Robert W McCarley; Robert Heinssen; Michael F Green; Keith Nuechterlein; Larry J Seidman Journal: Schizophr Res Date: 2016-02-16 Impact factor: 4.939
Authors: Waqas Ullah Khan; Zaid Ghazala; Heather Jane Brooks; Ponnusamy Subramaniam; Benoit H Mulsant; Sanjeev Kumar; Aristotle N Voineskos; Daniel M Blumberger; Robert S Kern; Tarek K Rajji Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306
Authors: Anne L Wheeler; M Mallar Chakravarty; Jason P Lerch; Jon Pipitone; Zafiris J Daskalakis; Tarek K Rajji; Benoit H Mulsant; Aristotle N Voineskos Journal: Schizophr Bull Date: 2013-07-20 Impact factor: 9.306
Authors: Sawsan M Kalache; Benoit H Mulsant; Simon J C Davies; Angela Y Liu; Aristotle N Voineskos; Meryl A Butters; Dielle Miranda; Mahesh Menon; Robert S Kern; Tarek K Rajji Journal: Schizophr Bull Date: 2014-08-06 Impact factor: 9.306